L
Lynn M. Schuchter
Researcher at University of Pennsylvania
Publications - 255
Citations - 27393
Lynn M. Schuchter is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 69, co-authored 236 publications receiving 22615 citations. Previous affiliations of Lynn M. Schuchter include Johns Hopkins University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Hezhe Lu,Shujing Liu,Gao Zhang,Lawrence N. Kwong,Yueyao Zhu,John P. Miller,Yi Hu,Wenqun Zhong,Jingwen Zeng,Lawrence Wu,Clemens Krepler,Katrin Sproesser,Min Xiao,Wei Xu,Giorgos C. Karakousis,Lynn M. Schuchter,Jeffery Field,Paul J. Zhang,Meenhard Herlyn,Xiaowei Xu,Wei Guo +20 more
TL;DR: The results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
Journal ArticleDOI
Disseminated melanoma--is there a new standard therapy?
DuPont Guerry,Lynn M. Schuchter +1 more
TL;DR: In white populations, the worldwide incidence of melanoma is higher than in other ethnic groups and the incidence of the disease is higher in women than in men.
Journal ArticleDOI
Melanoma Genetic Testing, Counseling, and Adherence to Skin Cancer Prevention and Detection Behaviors
Karen Glanz,Kathryn Volpicelli,Peter A. Kanetsky,Michael E. Ming,Lynn M. Schuchter,Christopher Jepson,Susan M. Domchek,Katrina Armstrong +7 more
TL;DR: Feedback of CD KN2A and MC1R genotype among families without known pathogenic CDKN2A mutations does not seem to decrease sun protection behaviors, and disclosure of this information did not have negative effects on prevention.
Journal ArticleDOI
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Melissa Wilson,Fengmin Zhao,Sanika Khare,Jason Roszik,Scott E. Woodman,Kurt D'Andrea,Bradley Wubbenhorst,David L. Rimm,John M. Kirkwood,Harriet M. Kluger,Lynn M. Schuchter,Sandra J. Lee,Keith T. Flaherty,Katherine L. Nathanson +13 more
TL;DR: Improved treatment response with CPS is observed in patients with melanoma whose tumors have RAF1 (cRAF), KRAS, or CCND1 amplification, all of which can be attributed to sorafenib targeting CRAF.
Journal ArticleDOI
Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Melissa Wilson,Fengmin Zhao,Richard Letrero,Kurt D'Andrea,David L. Rimm,John M. Kirkwood,Harriet M. Kluger,Sandra J. Lee,Lynn M. Schuchter,Keith T. Flaherty,Katherine L. Nathanson +10 more
TL;DR: This study of somatic mutations in melanoma is the last prospectively collected phase III clinical trial population before the era of BRAF-targeted therapy, and a trend toward improved clinical response in patients with NRAS-mutant melanoma treated with CPS was observed, possibly due to the effect of sorafenib on CRAF.